Introduction {#s1}
============

There are plenty of receptors that play an opposite or synergistic role in heart function ([@B29]). In the view of muscarinic acetylcholine receptors (MR), there are major subtypes (M~2~) and minor subtypes (M~1~, M~3~, maybe M~5~) in the heart, and the physiological and pathophysiological roles of these receptors have been uncovered ([@B7]; [@B33]; [@B13]; [@B5]; [@B12]; [@B11]; [@B32]). It has been reported that choline has some effects on M~3~ muscarinic acetylcholine receptor (M~3~R) in cardiac myocytes ([@B33]). This compound has been used as an agonist of muscarinic receptor in numerous published studies ([@B10]; [@B38]; [@B49]; [@B22]; [@B43]). Previous studies by our laboratory and others have demonstrated that activation of M~3~R protected against cardiac ischemia, cardiac hypertrophy, and arrhythmias ([@B28]; [@B21]). Specifically, activation of M~3~R by choline or overexpression of M~3~R in transgenic mice inhibits cardiac apoptosis, inflammation, calcium overload, and ion channel dysfunction ([@B45]; [@B19]; [@B20]; [@B41]). It is known that in the late phase of cardiac ischemia or hypertrophy, cardiac fibroblasts play an essential role in cardiac remodeling characterized by collagen overproduction and accumulation leading to cardiac interstitial fibrosis ([@B17]). While these studies primarily focused on the effects of M~3~R in cardiomyocytes, the function of M~3~R in cardiac fibroblasts and its potential role in cardiac fibrosis has not been exploited. Intriguingly, it has been documented that selective activation of M~3~R attenuates hepatic collagen deposition, bile ductule proliferation, and liver fibrosis ([@B16]). In contrast, a study reported that cholinergic stimuli mediated by muscarinic receptors induced the proliferation of fibroblasts and myofibroblasts in airway ([@B30]). A study reported by Organ et al. demonstrated that the inbred mice fed with choline has significantly enhanced cardiac fibrosis in a transverse aortic constriction (TAC) model ([@B25]). Another study conducted in a model of myocardial infarction reported that choline promotes cardiac fibrosis ([@B46]). All these studies suggest that M~3~R participates in the proliferation of fibroblasts and collagen production. However, the role of M~3~R in cardiac fibrosis remained controversial and inadequately addressed.

It has been well recognized that transforming growth factor (TGF)-β1/Smad cascade governs cardiac fibroblast proliferation and collagen secretion. For example, activation of the TGF-β1/Smad pathway promotes the growth of cardiac fibroblasts and collagen production ([@B48]). In contrast, inhibition of TGF-β1/Smad limits the progression of cardiac fibrosis ([@B27]). In addition, many other signaling pathways have also been uncovered to participate in the development and progress of cardiac fibrosis. Among them, the mitogen-activated protein kinase (MAPK) pathway constituted by p38MAPK, ERK, and JNK is crucial to cardiac fibrosis and structural remodeling ([@B40]). Importantly, modulation of the MAPK pathway controls the pathological changes of cardiac fibrosis ([@B27]).

Taken together the above background information, we set up the present study focusing on the role of M~3~R in cardiac fibrosis and the underlying mechanisms. Our results demonstrated for the first time that choline significantly inhibits cardiac fibroblast proliferation and collagen secretion, and this anti-fibrotic property is likely ascribed to the inhibition of the TGF-β1/Smad and MAPK pathways.

Materials and Methods {#s2}
=====================

Animals {#s2_1}
-------

Male Kunming mice and neonatal Sprague Dawley rats were purchased from the Animal Center of the Second Affiliated Hospital of Harbin Medical University (Harbin, China). The mice were maintained under standard animal room conditions (temperature, 21 ± 1°C; humidity, 55 to 60%), with food and water *ad libitum*. This study was conducted in strict accordance with the recommendations of the National Institutes of Health's "Guidelines for the Care and Use of Laboratory Animals" (NIH publication, revised 2011). The protocol was approved by the Animal Care and Use Committee of Harbin Medical University.

A total of 32 mice of 20∼25 g were used in our study. The mice were anesthetized with 2,2,2-tribromoethanol (270 mg/kg) and TAC model with excessive cardiac fibrosis was established ([@B23]). The sham-operated control mice underwent the same surgical procedures without ligation of the aortic bundle. Three days after TAC, the mice were divided into four experimental groups (n = 8): sham, TAC, TAC + choline (14 mg/kg), TAC + choline + 4-DAMP (4-diphenylacetoxy-*N*-methyl-piperidine, 14 mg/kg choline, 0.7 µg/kg 4-DAMP). For co-administration of choline and 4-DAMP, 4-DAMP was injected 30 min before choline treatment and the administration method was intraperitoneal injection. After 8 weeks, cardiac function of the survived mice was examined by echocardiography. For molecular biology studies, the hearts were isolated and then quickly striped, cleared in cold buffer, and weighed after drying. The left ventricle preparations were stored frozen in a −80°C freezer for subsequent Western blot experiments.

Cell Culture and Treatment {#s2_2}
--------------------------

Hearts of neonatal SD rats (1--3 days) were cut into pieces and gathered in 50 ml centrifugal tube with 0.25% trypsin. The cell suspensions was collected in Dulbecco's modified Eagle's medium (DMEM, Corning, USA) supplemented with 10% fetal bovine serum, 100 U/ml penicillin, and 100 µg/ml streptomycin. It was then incubated in culture flasks for 2 h, to allow for fibroblasts to adhere to the bottom of the culture flasks. Unattached cardiomyocytes and other cells were removed. Isolated fibroblasts were incubated at 37°C in a humidified atmosphere of 5% CO~2~ and 95% air and nourished at an interval of every 2--3 days. The purity of cardiac fibroblasts used in our study was validated by staining specific marker vimentin using immunofluorescence ([**Figure S1**](#SM1){ref-type="supplementary-material"}). The cardiac fibroblasts were pre-treated with 3 nM 4-DAMP in the presence or absence of choline (1, 5, or 10 mM) for 1 h and then incubated with 20 ng/ml TGF-β1 for 48 h. 4-DAMP was dissolved in dimethyl sulfoxide (DMSO) and diluted to a final concentration of DMSO \< 0.1%. The dose/concentration of M~3~ receptor 4-DAMP was selected according to previous studies ([@B39]; [@B50]).

Echocardiography and Histological Analysis {#s2_3}
------------------------------------------

Mice were anesthetized mice before echocardiography. Both two-dimensional M-mode and three-dimensional Doppler echocardiography were performed by using the Vevo 770 imaging system (VisualSonics, Toronto, Canada) to evaluate cardiac diameter and the function of heart.

Echocardiographic parameters included left ventricular ejection fraction (LVEF), left ventricular shortening score (LVFS), the left ventricular end-diastolic diameter (LVIDd), and left ventricular end-systole diameter (LVIDs) For histological analysis, the hearts were fixed with 4% paraformaldehyde (pH 7.4) for 48 h. The tissue was soaked in paraffin, cut into 5-µm sections, and stained with Masson trichrome. Collagen deposition was quantified by Image-Pro Plus software (Media Cybernetics, Silver Spring, USA).

Western Blot {#s2_4}
------------

Total protein samples were extracted from cardiac tissues and cardiac fibroblasts using lysis buffer. Protein sample (100 µg) was fractionated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (10% polyacrylamide gels) and transferred to nitrocellulose membrane. The membrane was blocked with 5% nonfat milk at room temperature for 2 h. The membrane was then incubated with primary antibodies for collagen I (1:500), collagen III (1:500), M~3~R (1;500), TGF-β1 (1:500), total Smad2/3 (t-Smad2/3; 1:1,000), phosphorylated Smad1/3 (p-Smad2/3; 1:1,000), t-ERK (1:1,000), p-ERK (1:1,000), t-P38 (1:1,000), p-p38 (1:1,000), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (1:1,000) on a shaking bed at 4°C overnight. The membrane was washed with PBS-Tween (0.5%) for three times and then incubated with secondary antibodies in the dark at room temperature for 1 h. Finally, the membranes were rinsed with PBS-T three times before being scanned by Imaging System (LI-COR Biosciences, Lincoln, NE, USA).

Ribonucleic Acid Extraction and Real-Time Reverse Transcription Polymerase Chain Reaction {#s2_5}
-----------------------------------------------------------------------------------------

Total RNA (0.5 µg) was extracted from cardiac fibroblasts by using TRIzol^™^ Reagent (Thermo, USA) according to the manufacturer's protocol. RNA concentration was measured and then reversely transcribed into complementary DNA. The messenger RNA (mRNA) levels of collagen I, collagen III, and TGF-β1 were determined using SYBR Green I incorporation method on LC480 Real-time PCR system (Roche, USA), with GAPDH as an internal control. The sequences of the primer pairs used in our study are as follow. Collagen I: forward (F): 5'-ATCAGCCCAAACCCCAAGGAGA-3' and reverse (R): 5'-CGCAGGAAGGTCAGCTGGATAG-3,' TGF-β1: F: 5'-CGCCTGCAGAGATTCAAGTCAAC-3' and R: 5'-GTATCAGTGGGGGTCAGCAGCC-3,' and GAPDH: F: 5'-TCCCTCAAGATTGTCAGCAA-3' and R: 5'-AGATCCACAACGGATACATT-3.'

Immunofluorescence {#s2_6}
------------------

Cardiac fibroblasts were cultured in an incubator for 48 h, then washed with PBS. Next, the cells were fixed with 4% paraformaldehyde solution for 20 min, permeabilized with 1% Triton X-100 (prepared by PBS) at room temperature for 60 min, and incubated with goat serum (Solarbio, Beijing, China) at 37°C for 30 min, following three washes with PBS. Subsequently, the cells were incubated with collagen I antibody (1:500) at 4°C overnight, followed by incubation with fluorescence secondary antibody (1:500) and Alexa Fluor^®^ 488-conjugated goat anti-rabbit IgG (H + L) secondary antibody (Life Technologies) as a control in the dark at room temperature for 1 h. 4′,6-Diamidino-2-phenylindole (DAPI) (10 mg/ml, Beyotime, Haimen, China) was used for nuclear staining. Images were obtained using an Olympus microscope (Japan).

Small Interference Ribonucleic Acid Transfection {#s2_7}
------------------------------------------------

Cardiac fibroblasts were transfected with an M~3~R small interference RNA (siRNA) or a scramble negative control (CTL) siRNA. Three siRNAs were used to screen the most potent sequence which was then used in subsequent experiments. The sequence of selected M~3~R siRNA was 5′-GCUACUGGCUGUGCUAUAUTTAUAUAGCACAGCCAGUAGCTT-3.′ Cells were transfected with 50 nM of siRNA using Lipofectamine 2000 (Invitrogen) for 6 h, before replacing with the medium containing 1% bovine serum. The cells were cultured for another 48 h. At 48 h after transfection, the cells were stimulated with TGF-β1 for 24 h and choline for an additional 24 h. The siRNA was constructed by GenePharma and transfected into cells according to the manufacturer's instructions.

Reagents {#s2_8}
--------

The recombinant human TGF-β1 was purchased from PeproTech (\#100-21, NJ, USA). Choline chloride was purchased from Sigma (C7527, ≧98% purity, USA). 4-DAMP was purchased from Abcam (ab120144, USA). Anti-M~3~ receptor antibody was provided by Alomone (AMR-006; Israel). Antibodies against t-Smad2/3 (\#8685), p-Smad2/3 (\#8828), TGF-β1 (\#3711), p38MAPK (\#9212), p-p38MAPK (\#9211), t-ERK1/2 (\#4695), and p-ERK1/2 (\#4370) were purchased from Cell Signaling Technology (CST, USA). Anti-collagen I antibody was purchased from Abcam (ab34710; Abcam, USA). Antibody against collagen III was purchased from Proteintech (13548-AP; Wuhan, China). Antibody against GAPDH was provided by ZSGB (TA-08; Beijing, China). Fluorescent secondary antibodies were purchased from LI-COR Biosciences (Lincoln, NE, USA).

Statistical Analysis {#s2_9}
--------------------

Data are presented as mean ± SEM. Comparison between two groups was performed using an unpaired Student's t-test. Comparisons among multiple groups were determined by one-way ANOVA followed by a *post hoc* Tukey test. The randomized block ANOVA (repeated measures ANOVA) was used for western blot data with a control value of 1 and no SEM as described previously ([@B18]). A value of p \< 0.05 was considered statistically significant.

Results {#s3}
=======

Protein Level of M~3~ Muscarinic Acetylcholine Receptor in Transforming Growth Factor Beta 1-Induced Cardiac Fibroblasts {#s3_1}
------------------------------------------------------------------------------------------------------------------------

Previous studies demonstrated that M~3~R is expressed in cardiomyocytes; however, whether this subtype of MR is also expressed in cardiac fibroblasts remained unknown. We therefore firstly detected protein level of M~3~R in cardiac fibroblasts using cardiomyocytes as a positive control group. As shown in [**Figure 1A**](#f1){ref-type="fig"}, protein level of M~3~R in cardiac fibroblasts was within the same range as that in cardiomyocytes. We then treated cardiac fibroblasts with 20 ng/ml TGF-β1 for 48 h to promote their proliferation. The mRNA levels of TGF-β1 and collagen I were significantly higher in TGF-β1-treated cells than in non-treated control cells ([**Figures 1B, C**](#f1){ref-type="fig"}). Moreover, TGF-β1 markedly elevated the protein level of M~3~R ([**Figure 1D**](#f1){ref-type="fig"}). These findings support that M~3~R is expressed in cardiac fibroblasts and can be activated in response to TGF-β1 stimulation.

![Protein level of M3 muscarinic acetylcholine receptor (M3R) in transforming growth factor beta 1 (TGF-β1)-induced cardiac fibroblasts (CF). **(A)** Protein level of M3R in CF and cardiomyocytes (CM). n = 3. **(B)** Effect of TGF-β1 (20 ng/ml, 48 h) on messenger RNA level of TGF-β1. \*\**p* \< 0.01 *vs.* Ctrl, n = 3. **(C)** Effect of TGF-β1 (20 ng/ml, 48 h) on mRNA level of collagen I. \*\*\**p* \< 0.001 *vs.* Ctrl, n = 3. **(D)** Effect of TGF-β1 (20 ng/ml, 48 h) on protein level of M~3~R in CF. \**p* \< 0.05 *vs.* Ctrl, n = 4.](fphar-10-01386-g001){#f1}

Effects of Choline on Protein Levels of Collagen in Cardiac Fibroblasts {#s3_2}
-----------------------------------------------------------------------

In order to investigate the effects of M~3~R on the proliferation of cardiac fibroblasts, we measured the protein levels of collagen I after treatment with a muscarinic acetylcholine receptor agonist choline at concentrations of 1, 5, and 10 mM. Both western blot and immunofluorescence results showed that collagen I was significantly decreased by 1 mM choline ([**Figures 2A, B**](#f2){ref-type="fig"}). And higher concentration of choline (5 and 10 mM) did not impose further inhibitory effects on collagen I levels. We therefore used 1 mM choline for subsequent experiments. As shown in [**Figures 2C, D**](#f2){ref-type="fig"}, compared with the TGF-β1 group, collagens I and III were significantly decreased by 1 mM choline, and this effect was abolished by adding 4-DAMP, a specific antagonist of M~3~R. These data suggested that activation of M~3~R significantly inhibits the secretion of collagen in cardiac fibroblasts.

![Effects of choline and 4-diphenylacetoxy-*N*-methylpiperidine methiodide (4-DAMP) on transforming growth factor beta 1 (TGF-β1)-induced collagen secretion. **(A)** Effects of different concentrations of choline (1, 5, 10 mM) on protein level of collagen I. \*\*\**p* \< 0.001 *vs.* Ctrl, ^\#\#^ *p* \< 0.01 *vs.* TGF-β1, n = 5. **(B)** Immunofluorescence for collagen I in cardiac fibroblasts (CF). Images were obtained using fluorescence microscopy. Blue fluorescence indicates 4′,6-diamidino-2-phenylindole, green fluorescence indicates collagen I, scale bars: 50 μm. \**p* \< 0.05 *vs.* Ctrl, ^\#^ *p* \< 0.05 *vs.* TGF-β1, n = 3. **(C)** Effect of choline on collagen I protein level in the different experimental groups. \**p* \< 0.05 *vs.* Ctrl, ^\#\#^ *p* \< 0.01 *vs.* TGF-β1, ^&&^ *p* \< 0.01 *vs.* choline, n = 7. **(D)** Effect of choline on collagen III protein level in the different experimental groups. \**p* \< 0.05 *vs.* Ctrl, ^\#^ *p* \< 0.05 *vs.* TGF-β1, ^&^ *p* \< 0.05 *vs.* choline, n = 6. **(E)** Effects of choline (1 mM) and 4-DAMP (3 nM) on protein level of M~3~ muscarinic acetylcholine receptor (M~3~R) in TGF-β1-treated CF. \**p* \< 0.05 *vs.* Ctrl, ^\#^ *p* \< 0.05 *vs.* TGF-β1, n = 5. **(F)** Protein level of M~3~R after transfecting with three fragments of M~3~R-siRNA. \**p* \< 0.05 *vs.* Ctrl, n = 4. **(G)** Protein level of collagen I after transfecting M~3~R-siRNA-3. \**p* \< 0.05 *vs.* Ctrl, n = 5.](fphar-10-01386-g002){#f2}

Furthermore, the protein level of M~3~R was further up-regulated by choline in cardiac fibroblasts pretreated with TGF-β1, which was partially but significantly reversed by 4-DAMP ([**Figure 2E**](#f2){ref-type="fig"}). These results suggest that M~3~R up-regulation and M~3~R activation are both involved in inhibiting collagen production in TGF-β1-treated cardiac fibroblasts.

Because choline and 4-DAMP are not highly specific ligands for M~3~R, siRNA of M~3~R siRNA was used by transfection to specifically silence the expression of M~3~R, and to validate the effects of M~3~R on the proliferation of cardiac fibroblasts. We examined three M~3~R siRNAs and selected the one with the highest silencing efficacy from them for subsequent experiments ([**Figure 2F**](#f2){ref-type="fig"}). As expected, silence of M~3~R promoted collagen production in cardiac fibroblasts treated with M~3~R siRNA compared with the control group ([**Figure 2G**](#f2){ref-type="fig"}).

Effects of Choline on Transverse Aortic Constriction-Induced Cardiac Dysfunction in Mice {#s3_3}
----------------------------------------------------------------------------------------

As shown in [**Figure 3A**](#f3){ref-type="fig"}, the heart size of TAC mice was obviously larger than sham control mice but was markedly reduced by choline. The effect of choline was abrogated by 4-DAMP. Consistently, both the ratios of heart weight to body weight and left ventricular weight to body weight of TAC mice were decreased by choline, which was reversed by 4-DMAP ([**Figures 3B, C**](#f3){ref-type="fig"}). No significant difference of the ratio of lung weight/body weight was found ([**Figure 3D**](#f3){ref-type="fig"}). Echocardiographic data revealed that LVEF was increased, while the thickness of the posterior wall of the left ventricle was significantly reduced by choline. These effects were weakened by 4-DAMP pretreatment ([**Figures 3F--H**](#f3){ref-type="fig"}), suggesting that M~3~R antagonism accounts at least partially for the cardiac dysfunction in TAC mice and choline improves the impaired cardiac function.

![Effects of choline on cardiac function of transverse aortic constriction (TAC) mice model. **(A)** Representative hearts from sham, TAC, and the mice induced by TAC treated with choline (14 mg/kg per day) and 4-DAMP (0.7 μg/kg/day) for 8 weeks. **(B)** The ratio of heart weight/body weight (BW). **(C)** The ratio of left ventricular weight (LVW)/BW. **(D)** The ratio of lung weight/body weight. **(E)** Representative echocardiographic images of mouse hearts in each group. **(F)** Left ventricular ejection fraction (LVEF). **(G)** Systolic left ventricular internal diameter (LVID, s). **(H)** Diastolic left ventricular internal diameter (LVID, d). \**p* \< 0.05, \*\**p*\< 0.01 *vs.* sham, ^\#^ *p* \< 0.05, ^\#\#^ *p* \< 0.01 *vs.* TAC, ^&^ *p* \< 0.05, ^&&^ *p* \< 0.01 *vs.* choline, n = 6.](fphar-10-01386-g003){#f3}

Effects of Choline on Cardiac Interstitial Fibrosis {#s3_4}
---------------------------------------------------

Masson staining shown in [**Figure 4A**](#f4){ref-type="fig"} revealed that choline treatment decreased the collagen-enriched area and attenuated the inflammatory cell infiltration of myocardial fibrosis induced by TAC, which was reversed by 4-DAMP. Meanwhile, the protein levels of collagens I and collagen III were found significantly higher in the TAC group than in the sham group, and this TAC-induced collagen deposition was essentially inhibited in the choline group ([**Figures 4B, C**](#f4){ref-type="fig"}). Meanwhile, protein level of M~3~R was increased in TAC mice compared to that in sham mice, and this upregulation was further exaggerated by choline but repressed by 4-DAMP ([**Figure 4D**](#f4){ref-type="fig"}). These results suggest that choline suppresses, whereas M~3~R inhibition facilitates cardiac fibrosis.

![Effects of choline on transverse aortic constriction (TAC)-induced myocardial fibrosis. **(A)** Representative heart section with Masson staining in the experimental groups, scale bar: 100 μm. \*\**p* \< 0.01 *vs.* sham, ^\#\#^ *p* \< 0.01 *vs.* TAC, ^&&^ *p* \< 0.01 *vs.* choline, n = 5. **(B)** Effects of choline and 4-diphenylacetoxy-*N*-methylpiperidine methiodide (4-DAMP) on the protein level of collagen I. \**p* \< 0.05 *vs.* sham, ^\#^ *p* \< 0.05 *vs.* TAC, ^&^ *p* \< 0.05 *vs.* choline, n = 8. **(C)** Effects of choline and 4-DAMP on the protein level of collagen III. \*\**p* \< 0.01 *vs.* sham, ^\#\#^ *p* \< 0.01 *vs.* TAC, n = 8. **(D)** Cardiac M~3~ muscarinic acetylcholine receptor protein level after TAC surgery and choline or 4-DAMP treatment. \**p* \< 0.05 *vs.* sham, ^\#\#^ *p* \< 0.01 *vs.*TAC, ^&&^ *p* \< 0.01 *vs.* choline, n = 8.](fphar-10-01386-g004){#f4}

Suppressive Effects of Choline on the Transforming Growth Factor Beta 1/Smad Pathway in Cardiac Fibroblasts and Transverse Aortic Constriction Mice {#s3_5}
---------------------------------------------------------------------------------------------------------------------------------------------------

The classical TGF-β1/Smad signaling pathway is a key determinant of cardiac fibrogenesis. Our Western blot results showed that the protein levels of TGF-β1 and Smad2/3 were significantly lower in the choline group than in the TGF-β1 group, 4-DAMP abolished the effects of choline ([**Figures 5A, B**](#f5){ref-type="fig"}). Similar results were consistently observed in TAC mice: the protein levels of TGF-β1 and p-Smad2/3 were substantially increased in TAC mice relative to those in sham control group. Moreover, choline mitigated the TAC-induced upregulation TGF-β1 and p-Smad2/3 levels and addition of 4-DAMP nearly entirely abolished the effects of choline ([**Figures 5C, D**](#f5){ref-type="fig"}).

![Effects of choline and 4-diphenylacetoxy-*N*-methylpiperidine methiodide (4-DAMP) on protein levels of transforming growth factor beta 1 (TGF-β1)/Smad2/3. **(A)** Effect of choline and 4-DAMP on TGF-β1 protein level in TGF-β1-induced cardiac fibroblasts (CF). \**p* \< 0.01 *vs.* Ctrl, ^\#\#\#^ *p* \< 0.001 *vs.* TGF-β1, n = 5. **(B)** Effect of choline and 4-DAMP on p-Smad2/3 protein level in TGF-β1-induced CF. \*\*\**p* \< 0.001 *vs.* Ctrl, ^\#^ *p* \< 0.05 *vs.* TGF-β1, ^&^ *p* \< 0.05 *vs.* choline, n = 6. **(C)** Effects of choline and 4-DAMP on the protein level of TGF-β1 in transverse aortic constriction (TAC) mice hearts. \**p* \< 0.05 *vs.* sham, ^\#\#^ *p* \< 0.01 *vs.* TAC, ^&^ *p* \< 0.05 *vs.* choline, n = 6. **(D)** Effects of choline and 4-DAMP on the protein level of p-smad2/3 in TAC mice hearts. \**p* \< 0.5 *vs.* sham, ^\#^ *p* \< 0.05 *vs.* TAC, n = 4.](fphar-10-01386-g005){#f5}

Suppressive Effects of Choline on Mitogen-Activated Protein Kinase Signaling in Cardiac Fibroblasts and Transverse Aortic Constriction Mice {#s3_6}
-------------------------------------------------------------------------------------------------------------------------------------------

It is well known that the MAPK signaling pathway plays an important role in myocardial ischemia and cardiac hypertrophy. We therefore next explored the potential relationship between M~3~R and MAPK signaling. On one hand, the ratio of p-p38/t-p38, and of p-ERK1/2/t-ERK1/2 in the choline group were significantly lower than in the TGF-β1 group, while 4-DAMP eliminated the suppressive effect of choline on p-p38, it failed to affect the effect of choline on p-ERK1/2 ([**Figures 6A, B**](#f6){ref-type="fig"}). On the other hand, protein levels of p-p38MAPK and p-ERK were increased in the TAC group compared with the sham group, and choline abrogated such increases while 4-DAMP partially prevented the suppressive effect of choline ([**Figures 6C, D**](#f6){ref-type="fig"}). These findings suggesting that M~3~R activation inhibits activation of p38 and ERK1/2 thereby MAPK signaling.

![Effect of choline and 4-diphenylacetoxy-*N*-methylpiperidine methiodide (4-DAMP) on protein levels of p38MAPK and ERK1/2. **(A)** Effect of choline and 4-DAMP on p-p38 protein level in transforming growth factor beta 1 (TGF-β1)-induced cardiac fibroblasts (CF). \*\**p* \< 0.01 *vs.* Ctrl, ^\#\#^ *p* \< 0.01 *vs.* TGF-β1, ^&&^ *p* \< 0.01 *vs.* choline, n = 5. **(B)** Effect of choline and 4-DAMP on p-ERK1/2 protein level in TGF-β1-induced CF. \*\**p* \< 0.01 *vs.* Ctrl, ^\#\#^ *p* \< 0.01 *vs.* TGF-β1, n = 6. **(C)** Effects of choline and 4-DAMP on the protein level of p-p38 in transverse aortic constriction (TAC) mice hearts. \**p* \< 0.05 *vs.* sham, ^\#^ *p* \< 0.05 *vs.* TAC, ^&^ *p* \< 0.05 *vs.* choline, n = 5. **(D)** Effects of choline and 4-DAMP on the protein level of p-ERK in TAC mice hearts. \**p* \< 0.05 *vs.* sham, ^\#^ *P*\< 0.05 *vs.* TAC, n = 4.](fphar-10-01386-g006){#f6}

Discussion {#s4}
==========

Although accumulating evidence has supported that M~3~R is expressed in cardiomyocytes of both human and rodents ([@B9]; [@B13]; [@B36]; [@B35]; [@B42]; [@B37]; [@B2]), its expression, and function in cardiac fibroblasts remained vaguely understood. To shed light on this issue, we conducted the present study focusing on the possible role M~3~R in regulating proliferation and collagen production of rat cardiac fibroblasts *in vitro* and cardiac fibrosis in TAC mice *in vivo*. The results demonstrated for the first time that M~3~R is expressed in cardiac fibroblasts of rodents, and either pharmacological inhibition or expression silence of M~3~R favors, while choline that has the potential to activate M~3~R limits cardiac fibrosis by inhibiting p38MAPK signaling.

It has been accepted that M~2~R is not the only functional subtype muscarinic and nicotinic acetylcholine receptors (mAChRs) in the heart ([@B32]). Numerous studies have reported that M~3~R plays an important role in heart diseases ([@B8]; [@B44]). However, these studies primarily focused on cardiomyocytes and no studies have reported the expression and function of M~3~R in cardiac fibroblasts, though it has been shown that M~3~R is expressed in certain types of non-cardiac fibroblasts. For example, Pieper et al. demonstrated that M~1~, M~2~, and M~3~ receptors are expressed at the mRNA level in lung fibroblasts. They also found that cholinergic stimuli mediated by muscarinic receptors cause remodeling in chronic airway disease ([@B30]). Reina et al. reported that pilocarpine activates muscarinic M~1~ and M~3~ receptors, which promotes apoptosis in human skin fibroblast cells ([@B31]). Here, we demonstrate that M~3~R proteins are presented in both cardiac fibroblasts and cardiomyocytes with similar abundance. Previous studies by ours and other laboratories suggest that choline produces a protective effect against cardiac hypertrophy by activating M~3~R ([@B39]; [@B21]; [@B43]). For example, Xu et al. observed significant attenuation of cardiac fibrosis after choline treatment in cardiac hypertrophy model ([@B43]). However, the mechanism for the anti-fibrotic effect of choline is unclear. The present study provided direct evidence of the anti-fibrotic effect of choline *via* acting on M~3~R. This note was well supported by the data we obtained using M~3~R-selective antagonist 4-DAMP and M~3~R-specific siRNA. Notably, we found that 1 mM choline produced maximum anti-fibrotic effects and increasing concentrations up to 10 mM did not yield further effects. As already mentioned earlier, two published studies demonstrated that choline promotes cardiac fibrosis in mouse models of TAC and myocardial infarction as well ([@B25]; [@B46]), which is in contradiction to the findings presented in the present study. The discrepancy could be explained by the following possibilities. First, in the two published studies, the authors ascribed the results to the microbiome conversion of choline to trimethylamine N-oxide (TMAO) as the animals were fed with choline diet; in other words, the observed enhancement of cardiac fibrosis by choline diet is primarily caused by TMAO. However, such an explanation might not be applied to our case because in our *in vivo* experiments, choline chloride was intraperitoneally injected into mice, and it is unlikely that choline undergoes microbiome conversion to TMAO. Second, in our *in vitro* study, fibroblasts were incubated directly with choline and again it is unlikely for choline to convert to TMAO either. Third, the fact that the beneficial action of choline was efficiently reversed by 4-DAMP suggests that in our models, choline likely acts directly on M~3~R without an involvement of TMAO or other factors.

It is well established that the MAPK pathway plays an important role in cardiac fibrosis by modulating the proliferation and differentiation of cardiac fibroblasts ([@B6]). Cardiac fibroblast-specific p38α MAPK causes cardiac ventricular remodeling and fibrosis promotes cardiac hypertrophy *via* regulating interleukin-6 signaling. Conversely, fibroblast-specific p38α knockout mice exhibits marked protection against myocardial injury and fibrosis ([@B3]). Moreover, a previous study also suggests that activation of M~3~R by choline relieves cardiac ischemia and hypertrophy by inhibiting p38MAPK signaling ([@B39]). The present study shows that the negative impact of M~3~R on p38MAPK also exists in cardiac fibroblasts.

In the present study, we used choline as an agonist of M~3~R; however, it must be noted that though the ability of choline to activate M~3~R has been documented by numerous studies, this compound is not a selective M~3~R agonist. Instead, choline has been shown to produce a variety of cellular functions. For instance, it was demonstrated that choline can be uptaken by transporters and then it activates sigma-1 receptors (Sig-1R), a group of integral membrane proteins of endoplasmic reticulum and potentiates Ca^2+^ signals ([@B4]). Evidence was provided in this study that choline mimics other Sig-1R agonists by potentiating Ca^2+^ signals evoked by the inositol 1,4,5-trisphosphate receptors. The authors conclude that choline is an endogenous agonist of Sig-1Rs linking extracellular stimuli to Ca^2+^ signals. It is also noted that this study reports a choline displacement of Sig-1R specific radioligand binding by \[^3^H\](+)-pentazocine with pKi value of around 3.3 mM, which is essentially in the same range of choline for M~3~R as reported by [@B33]. Together these findings, it appears that choline is a non-selective agonist for both M~3~R and Sig-1R and maybe for other receptors too. Another study demonstrated that Sig-1R knockout mice have significantly increased cardiac fibrosis and collagen deposition in the hearts, indicating an involvement of Sig-1R in regulating cardiac fibrosis ([@B1]). A most recent report demonstrates that BD1047 (an antagonist of Sig-1R can cause an increase in atrial fibrosis contributing to exacerbating atrial fibrillation ([@B47]). Due to the present lack of subtype-selective mAChR agonists, we employed choline as a partial agonist of M~3~R in the present study. Precaution must therefore be taken in interpreting our results obtained with choline in terms of the mechanism of action; in other words, the present study does not exclude the possibility of choline to interact with Sig-1R and produce the anti-fibrotic action. Nonetheless, it should also be noted that there has not been any evidence for the presence of Sig-1R in cardiac fibroblasts, with which the present study was conducted.

The study reported by Jaiswal et al. in 1989 ([@B14]) stands the first evidence for functional M~3~R in mammalian hearts, which was verified the same group in 1996 in ventricular myocytes of rabbit hearts ([@B15]). The existence of M~3~R in cardiomyocytes has been recognized by several more confirmative studies from multiple research groups with pharmacological, functional, and molecular evidence ([@B13]; [@B24]; [@B26]; [@B37]). Nevertheless, whether M~3~R also exists in cardiac fibroblasts remained unknown prior to the present study; thus, we present here the first evidence for the expression and function of M~3~R in cardiac fibroblasts. Though our study does not provide conclusive evidence, the most rational and objective explanation of our data is the participation of M~3~R in cardiac fibrosis.

In addition to M~2~R and M~3~R, the heart also expressed other subtypes of mAChRs, including M~1~R ([@B7]; [@B12]) and M~4~R ([@B7]; [@B34]; [@B37]). The presence of M~1~R and M~2~R proteins on the surface membrane of the cultured rat ventricular myocytes was confirmed by immunofluorescence ([@B7]). The study suggests that the positive chronotropic effect of mAChR activation on the contractions is mediated through the M~1~R coupled through Gq to phospholipase C-induced phosphoinositide hydrolysis. In contrast, a study suggests the absence of M~1~R expression in mouse heart ([@B12]). This conclusion was primarily based on the following two pieces of evidence. First, basal values of heart rate, developed left ventricular pressure, left ventricular dP/dt~max~, and mean blood pressure are similar between wild type and M~1~R-knockout mice. Second, administration of M~1~R-selective agonist McN-A-343 increases hemodynamic function in wild-type mice but fails to cause any changes in M~1~R knockout mice.

Regarding the statistical analysis applied to western blots, calculating the average of all data from different batches of experiments represents an appropriate and more powerful analysis. However, in our study, western blot experiments presented too much variability in batches of experiments, so we normalized the data to control in each western blot gel firstly, then analyzed the normalized data from different batches. This might represent a limitation of the study, which should be validated in future study.

In conclusion, our study suggests that choline significantly inhibits cardiac fibroblast proliferation and collagen secretion likely *via* activating M~3~R with the functional role of which being associated with the TGF-β1/Smad and p38MAPK pathways.

Data Availability Statement {#s5}
===========================

The raw data supporting the conclusions of this manuscript will be made available by the authors, without undue reservation, to any qualified researcher.

Ethics Statement {#s6}
================

The animal study was reviewed and approved by Ethical Committee of Harbin Medical University.

Author Contributions {#s7}
====================

LZ, TC: acquisition, analysis, and interpretation of data. PH: analysis and interpretation of data, and manuscript writing. JG, WL, YP, JD, YZ: acquisition of data. ZD: conception and design, manuscript revision, and final approval of manuscript.

Funding {#s8}
=======

This work was supported by National Natural Science Foundation of China (No. 81673424 and 81300080).

Conflict of Interest {#s9}
====================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Supplementary Material {#s10}
======================

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fphar.2019.01386/full#supplementary-material>

###### 

Click here for additional data file.

[^1]: Edited by: Gianluigi Pironti, Karolinska Institutet (KI), Sweden

[^2]: Reviewed by: Jaromir Myslivecek, Charles University, Czechia; JoAnn Trial, Baylor College of Medicine, United States

[^3]: This article was submitted to Cardiovascular and Smooth Muscle Pharmacology, a section of the journal Frontiers in Pharmacology

[^4]: †These authors have contributed equally to this work
